Literature DB >> 1831632

Methodology in anti-emetic trials.

R J Gralla1, R A Clark, M G Kris, L B Tyson.   

Abstract

Major progress in the ability to control chemotherapy-induced emesis has been made over the past 10 years. One of the several factors contributing to this improved control has been the development of accurate assessment methodology. The application of proper study methodology fostered the identification of active single agents and led to the formation of effective anti-emetic combinations. In this communication, important areas in anti-emetic study evaluation will be outlined. Proper methodology includes selection of agents or regimens that have a good rationale for study. Patient, chemotherapy, and anti-emetic factors must be controlled or standardised in good trial design, and the evaluation techniques for determining the amount of emesis or of nausea must be performed using reliable and valid methods. The statistical design employed and number of patients entered in the trial should be determined based on achievable and relevant goals.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1831632

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance).

Authors:  Debra L Barton; Gita Thanarajasingam; Jeff A Sloan; Brent Diekmann; Jyotsna Fuloria; Lisa A Kottschade; Alan P Lyss; Anthony J Jaslowski; Miroslaw A Mazurczak; Scott C Blair; Shelby Terstriep; Charles L Loprinzi
Journal:  Cancer       Date:  2014-07-09       Impact factor: 6.860

Review 2.  Delayed emesis: a dilemma in antiemetic control.

Authors:  R A Clark; R J Gralla
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

Review 3.  Methodology of trials with antiemetics.

Authors:  M Tonato; F Roila; A Del Favero; E Ballatori
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

4.  Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment.

Authors:  H Bleiberg; S Van Belle; R Paridaens; G De Wasch; L Y Dirix; M Tjean
Journal:  Drugs       Date:  1992       Impact factor: 9.546

5.  Methodology and assessment in clinical anti-emetic research: a meta-analysis of outcome parameters.

Authors:  G R Morrow
Journal:  Br J Cancer Suppl       Date:  1992-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.